We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease (GATEWAY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04537377
Recruitment Status : Recruiting
First Posted : September 3, 2020
Last Update Posted : April 24, 2023
Information provided by (Responsible Party):
Vivet Therapeutics SAS

Brief Summary:
The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and following background WD therapy withdrawal.

Condition or disease Intervention/treatment Phase
Wilson's Disease Genetic: VTX-801 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Intervention Model Description: Dose escalation study
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients With Wilson's Disease
Actual Study Start Date : September 3, 2021
Estimated Primary Completion Date : March 2024
Estimated Study Completion Date : March 2029

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Wilson Disease

Arm Intervention/treatment
Experimental: VTX-801 Genetic: VTX-801

The investigational medicinal product (VTX-801) is a replication-deficient recombinant adeno-associated viral vector (rAAV) consisting of an AAV liver tropic capsid containing a single-stranded DNA genome carrying a shortened version of the ATP7B gene (ATP7B-minigene).

After reconstitution VTX-801 will be administered as a single dose intravenous (IV) administration per patient, at up to 3 different dose levels.

Primary Outcome Measures :
  1. Safety and tolerability profile (including treatment-emergent adverse events (TEAE)) [ Time Frame: at 1-Year post treatment ]
    AEs will be summarized based on the date of onset for the event. Number of treatment-emergent AEs will be provided by SOC and PT, by dose cohort and overall.

Secondary Outcome Measures :
  1. Free serum Cu [ Time Frame: at 1-Year post treatment ]
    Free serum Cu will be summarized descriptively for all patients by dose cohort and planned visit, for absolute values, changes from baseline and percent change from baseline.

  2. Total serum Cu [ Time Frame: at 1-Year post treatment ]
    Total serum Cu will be summarized descriptively for all patients by dose cohort and planned visit, for absolute values, changes from baseline and percent change from baseline.

  3. 24-hour urinary Cu [ Time Frame: at 1-Year post treatment ]
    24-hour urinary Cu will be summarized descriptively for all patients by dose cohort and planned visit, for absolute values, changes from baseline and percent change from baseline.

  4. Serum ceruloplasmin activity (enzymatic assay) [ Time Frame: at 1-Year post treatment ]
    Serum ceruloplasmin will be summarized descriptively for all patients by dose cohort and planned visit, for absolute values, changes from baseline and percent change from baseline.

  5. VTX-801 Responder status [ Time Frame: At Week 12 and Week 36 ]
    The number of Responders and Insufficient-Responders will be summarized by dose cohort and planned visit, with response to treatment.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  • Male or female aged between 18 and 65 years
  • Confirmed diagnosis of WD
  • Treated for WD according to international recommendations with no current evidence for inadequate treatment
  • Stable WD for ≥ 1 year, defined as: (i) No significant change in neurologic examination and in status of mood disorder and (ii) Stable laboratory parameters used to assess copper metabolism

Main Exclusion Criteria:

  • ALT level ≥ 2 ULN that is not readily explained by extrinsic factors
  • Total bilirubin > 1.5 x ULN in the absence of proven Gilbert's syndrome; in case of Gilbert's syndrome, direct bilirubin > ULN
  • INR > ULN
  • Any signs of liver cirrhosis decompensation, including gastrointestinal bleed within 6 months (24 weeks) prior to screening/enrolment visit
  • Patient has moderate or severe renal impairment defined as eGFR CKD-EPI < 60 mL/min/1.73 m2, or patient has nephritis or nephrotic syndrome
  • Any history or current evidence of HIV-1, HIV-2, HTLV 1, or HTLV-2 infection
  • Any history or current evidence of hepatitis B infection
  • Any history of hepatitis C infection, unless previous viral RNA assays in two samples, collected at least 6 months apart, are negative
  • Positive QuantiFERON®-TB Gold tuberculosis test result
  • Any concomitant disorder/condition - including hepatic disorders - or treatment possibly interfering with the conduct or evaluation of the study
  • Any history of diabetes
  • Pregnancy or breastfeeding
  • Body Mass Index ≥ 35 kg/m2

Other protocol defined Inclusion/ Exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04537377

Layout table for location contacts
Contact: Sonia Valero +33 1 83 81 17 10 info@vivet-therapeutics.com

Layout table for location information
United States, California
UC Davis Medical Center Recruiting
Sacramento, California, United States, 95817
Contact: Sandeep Dhaliwal    916-734-8696    sandhaliwal@UCDAVIS.EDU   
Principal Investigator: Valentina Medici, Dr         
United States, Connecticut
Yale University School of Medecine Recruiting
New Haven, Connecticut, United States, 06510
Contact: Daksshi Hettiarachchi    203-737-5037    daksshi.hettiarachchi@yale.edu   
Principal Investigator: Michael Schilsky, Dr         
United States, Florida
Advent Health Recruiting
Orlando, Florida, United States, 32803
Contact: Calla Boatright    407-303-5600 ext 112-3143    Calla.Boatright@AdventHealth.com   
Principal Investigator: Regino Gonzalez-Peralta, Dr         
United States, Michigan
University of Michigan Health System Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Ashley Page    734-998-9966    ashpage@med.umich.edu   
Principal Investigator: Frederick Askari, Dr         
United States, North Carolina
Wake Forest School of Medicine Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Dee Faust    336-713-1442    delannin@wakehealth.edu   
Principal Investigator: Sean Rudnick, Dr         
United States, Texas
University of Texas Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75235
Contact: Dolores Santoyo    214-648-4412    dolores.santoyo@utsouthwestern.edu   
Principal Investigator: William Lee, Dr         
Aarhus University Hospital Recruiting
Aarhus, Denmark, 8200
Contact: Thomas Sandhal, Dr    +45 51504813    thomsand@rm.dk   
Principal Investigator: Thomas Sandhal, Dr         
Universitätsklinikum Tübingen (UKT) Recruiting
Tübingen, Germany, 72076
Contact: Ulrich Lauer, Dr    +49 7071-2983190    ulrich.lauer@med.uni-tuebingen.de   
Principal Investigator: Ulrich Lauer, Pr         
United Kingdom
Royal Surrey County Hospital Recruiting
Guildford, Surrey, United Kingdom, GU2 7XX
Contact: Aftab Ala, Dr.    (+44) 1483 571 122    aftabala@nhs.net   
Principal Investigator: Aftab Ala, Dr.         
Sponsors and Collaborators
Vivet Therapeutics SAS
Layout table for additonal information
Responsible Party: Vivet Therapeutics SAS
ClinicalTrials.gov Identifier: NCT04537377    
Other Study ID Numbers: VTX-801_CLN_001
2020-000963-22 ( EudraCT Number )
First Posted: September 3, 2020    Key Record Dates
Last Update Posted: April 24, 2023
Last Verified: April 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatolenticular Degeneration
Liver Diseases
Digestive System Diseases
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Movement Disorders
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Metal Metabolism, Inborn Errors
Metabolic Diseases